Published in Thromb Res on November 15, 2000
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost (2014) 2.38
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost (2013) 2.05
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost (2012) 2.04
The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood (1986) 1.98
Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet (2000) 1.95
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther (2007) 1.95
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost (2009) 1.92
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med (1998) 1.90
Propofol versus sevoflurane for fiberoptic intubation under spontaneous breathing anesthesia in patients difficult to intubate. Minerva Anestesiol (2010) 1.70
IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol (1994) 1.62
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. J Thromb Haemost (2009) 1.55
Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost (2008) 1.51
The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost (2008) 1.50
False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. J Thromb Haemost (2011) 1.45
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol (1992) 1.43
A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost (2004) 1.42
Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Intern Emerg Med (2007) 1.41
The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation. J Thromb Haemost (2012) 1.40
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus (2005) 1.38
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost (2006) 1.27
Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost (1997) 1.27
Activated protein C resistance in deep-vein thrombosis. Lancet (1994) 1.22
Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology (2002) 1.22
Gall bladder sludge formation during prolonged fasting after gastrointestinal tract surgery. Gut (1985) 1.19
Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis (2002) 1.19
Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma (2003) 1.15
Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol (2010) 1.14
Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood (1987) 1.12
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11
Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation (2009) 1.07
Surgical margins of resection for breast cancer: current evidence. Minerva Chir (2012) 1.06
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost (2011) 1.06
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica (2001) 1.06
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost (2010) 1.06
Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost (2011) 1.05
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol (1999) 1.05
Panic disorder: cognitive-behavioral treatment. Behav Res Ther (1990) 1.05
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost (2008) 1.04
Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis (1990) 1.03
A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost (2000) 1.03
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost (2001) 1.02
The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg (1995) 1.01
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost (2008) 1.00
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood (1999) 1.00
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost (2012) 0.99
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia (2000) 0.99
Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost (1995) 0.98
Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. Eur J Intern Med (2013) 0.97
Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med (2011) 0.97
Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ (2001) 0.96
The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol (2000) 0.95
Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. Br J Anaesth (1993) 0.95
Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. J Orthop Traumatol (2011) 0.93
Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol (2001) 0.93
Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost (1996) 0.92
Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol (1997) 0.92
Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. Int Angiol (2009) 0.92
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. Thromb Haemost (2011) 0.91
Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med (2000) 0.90
Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus (2012) 0.90
Midazolam for premedication in children: nasal vs. rectal administration. Eur J Anaesthesiol (1997) 0.90
Nutrient mitigation capacity in Mississippi Delta, USA drainage ditches. Environ Pollut (2009) 0.89
The role of trauma and dissociation in cognitive-behavioral psychotherapy outcome and maintenance for panic disorder with agoraphobia. Behav Res Ther (1998) 0.89
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol (1997) 0.89
Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost (2010) 0.89
Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia (2011) 0.89
Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost (1999) 0.89
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg (2010) 0.88
Prevention of venous thrombosis with elastic stockings during long-haul flights: the LONFLIT 5 JAP study. Clin Appl Thromb Hemost (2003) 0.88
p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro. J Neurochem (2002) 0.88
Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) (2010) 0.88
High blood ketone body concentration in type 2 non-insulin dependent diabetic patients. J Endocrinol Invest (1996) 0.88